Why ProMIS Neurosciences Stock Surged Today
Portfolio Pulse from Ryan Gustafson
ProMIS Neurosciences Inc. (NASDAQ:PMN) shares surged after the company presented preclinical data supporting the potential therapeutic advantage of its lead candidate for Alzheimer's disease, PMN310, at AAIC 2023. The company also received clearance from the FDA for its Investigational New Drug (IND) application for PMN310. Shares of PMN were up 113.5% at $6.00 at the time of publication.
July 17, 2023 | 6:22 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ProMIS Neurosciences' stock surged after positive preclinical data for its Alzheimer's drug, PMN310, and FDA clearance for its IND application. The stock was up 113.5% at $6.00.
The surge in ProMIS Neurosciences' stock price can be attributed to the positive preclinical data for its Alzheimer's drug, PMN310, and the FDA clearance for its IND application. These developments are likely to boost investor confidence in the company's potential for growth and profitability, leading to increased demand for its shares.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100